Summit Therapeutics (SMMT) Stock Forecast & Price Target

Compare

1,836 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SMMT Analyst Ratings

Moderate Buy

8 Buy

2 Hold

3 Sell

Based on 13 analysts giving stock ratings to

Summit

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SMMT Stock 12 Month Forecast

Average Price Target

$38.99

▲(116.73% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $38.99 with a high forecast of $131.90 and a low forecast of $13.00. The average price target represents a 116.73% change from the last price of $17.99.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","42":"$42","72":"$72","102":"$102","132":"$132"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":131.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$131.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.99,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,42,72,102,132],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.26,26.07846153846154,34.89692307692307,43.715384615384615,52.533846153846156,61.35230769230769,70.17076923076922,78.98923076923077,87.8076923076923,96.62615384615384,105.44461538461537,114.26307692307692,123.08153846153846,{"y":131.9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.26,18.931538461538462,20.603076923076927,22.274615384615387,23.946153846153848,25.61769230769231,27.28923076923077,28.960769230769234,30.632307692307695,32.30384615384615,33.97538461538461,35.64692307692308,37.31846153846154,{"y":38.99,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.26,16.932307692307695,16.604615384615386,16.27692307692308,15.94923076923077,15.621538461538462,15.293846153846154,14.966153846153848,14.638461538461538,14.310769230769232,13.983076923076922,13.655384615384616,13.327692307692308,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.49,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$131.90

Average Price Target$38.99

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yigal Nochomovitz

Citi

$40→$131.9

Buy

633.19%

Upside

Reiterated

12/02/25

Citi Keeps Their Buy Rating on Summit Therapeutics (SMMT)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Summit Therapeutics initiated with a Peer Perform at Wolfe ResearchSummit Therapeutics initiated with a Peer Perform at Wolfe Research

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/10/25

Positive Outlook for Summit Therapeutics Amid Strategic Clinical AdvancementsWe updated our model following Summit's Q3 earnings report during ESMO, and we discussed the earnings details in our management dinner note here and HARMONi-6 ESMO note here. We altered our expense estimates in-line with the ongoing Phase III trials and anticipated initiation of the Phase III HARMONi-GI3 trial. We maintain our Buy rating.

William Maughan

Clear Street

$32

Buy

77.88%

Upside

Reiterated

11/10/25

Clear Street Remains a Buy on Summit Therapeutics (SMMT)

David Dai

UBS

$30→$33

Buy

83.44%

Upside

Reiterated

11/10/25

Summit Therapeutics (SMMT) Gets a Buy from UBS

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

11/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), ANI Pharmaceuticals (NASDAQ: ANIP) and Summit Therapeutics (NASDAQ: SMMT)

Daina Graybosch

Leerink Partners

―

Sell

―

Reiterated

10/22/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Viatris (NASDAQ: VTRS)We continue to rate SMMT UP, as we believe the company needs a biopharma partner to support ivonescimab’s complex global development.

Etzer Darout

Barclays

$13→$16

Sell

-11.06%

Downside

Reiterated

10/21/25

Barclays Remains a Sell on Summit Therapeutics (SMMT)

Mohit Bansal

Wells Fargo

$30

Buy

66.76%

Upside

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)Our Thoughts—A Partner Would Be Good at This Point

Mitchell Kapoor

H.C. Wainwright

$50→$40

Buy

122.35%

Upside

Reiterated

10/21/25

Summit Therapeutics price target lowered to $40 from $50 at H.C. WainwrightSummit Therapeutics price target lowered to $40 from $50 at H.C. Wainwright

Cory Kasimov

Evercore ISI

$34

Buy

88.99%

Upside

Reiterated

10/20/25

Evercore ISI Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

Kelsey Goodwin

Piper Sandler

$21

Hold

16.73%

Upside

Reiterated

10/20/25

Piper Sandler Reaffirms Their Hold Rating on Summit Therapeutics (SMMT)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$13

Sell

-27.74%

Downside

Initiated

09/17/25

Summit Therapeutics (SMMT) Gets a Sell from Roth MKM

Reni Benjamin

Citizens JMP

$40

Buy

122.35%

Upside

Reiterated

09/08/25

Citizens JMP Remains a Buy on Summit Therapeutics (SMMT)Citizens JMP analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

Bradley Canino

Guggenheim

$40

Buy

122.35%

Upside

Initiated

09/03/25

Summit Therapeutics initiated with a Buy at GuggenheimSummit Therapeutics initiated with a Buy at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yigal Nochomovitz

Citi

$40→$131.9

Buy

633.19%

Upside

Reiterated

12/02/25

Citi Keeps Their Buy Rating on Summit Therapeutics (SMMT)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Summit Therapeutics initiated with a Peer Perform at Wolfe ResearchSummit Therapeutics initiated with a Peer Perform at Wolfe Research

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/10/25

William Maughan

Clear Street

$32

Buy

77.88%

Upside

Reiterated

11/10/25

Clear Street Remains a Buy on Summit Therapeutics (SMMT)

David Dai

UBS

$30→$33

Buy

83.44%

Upside

Reiterated

11/10/25

Summit Therapeutics (SMMT) Gets a Buy from UBS

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

11/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), ANI Pharmaceuticals (NASDAQ: ANIP) and Summit Therapeutics (NASDAQ: SMMT)

Daina Graybosch

Leerink Partners

―

Sell

―

Reiterated

10/22/25

Etzer Darout

Barclays

$13→$16

Sell

-11.06%

Downside

Reiterated

10/21/25

Barclays Remains a Sell on Summit Therapeutics (SMMT)

Mohit Bansal

Wells Fargo

$30

Buy

66.76%

Upside

Reiterated

10/21/25

Mitchell Kapoor

H.C. Wainwright

$50→$40

Buy

122.35%

Upside

Reiterated

10/21/25

Summit Therapeutics price target lowered to $40 from $50 at H.C. WainwrightSummit Therapeutics price target lowered to $40 from $50 at H.C. Wainwright

Cory Kasimov

Evercore ISI

$34

Buy

88.99%

Upside

Reiterated

10/20/25

Evercore ISI Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

Kelsey Goodwin

Piper Sandler

$21

Hold

16.73%

Upside

Reiterated

10/20/25

Piper Sandler Reaffirms Their Hold Rating on Summit Therapeutics (SMMT)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$13

Sell

-27.74%

Downside

Initiated

09/17/25

Summit Therapeutics (SMMT) Gets a Sell from Roth MKM

Reni Benjamin

Citizens JMP

$40

Buy

122.35%

Upside

Reiterated

09/08/25

Citizens JMP Remains a Buy on Summit Therapeutics (SMMT)Citizens JMP analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

Bradley Canino

Guggenheim

$40

Buy

122.35%

Upside

Initiated

09/03/25

Summit Therapeutics initiated with a Buy at GuggenheimSummit Therapeutics initiated with a Buy at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Summit Therapeutics

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

-0.44%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of -0.44% per trade.

3 Months

xxx

Success Rate

6/6 ratings generated profit

Average Return

+22.63%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +22.63% per trade.

1 Year

Bradley CaninoGuggenheim

Success Rate

5/7 ratings generated profit

Average Return

+230.80%

initiated a buy rating 3 months ago

Copying Bradley Canino's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +230.80% per trade.

2 Years

xxx

Success Rate

4/7 ratings generated profit

Average Return

+161.93%

initiated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +161.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SMMT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SMMT has received 17 Buy Ratings, 2 Hold Ratings, and 2 Sell Ratings. SMMT average Analyst price target in the past 3 months is 38.99.

Each month's total comprises the sum of three months' worth of ratings.

SMMT Financial Forecast

SMMT Earnings Forecast

Next quarter’s earnings estimate for SMMT is -$0.24 with a range of -$0.33 to -$0.12. The previous quarter’s EPS was -$0.31. SMMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Sales Forecast

Next quarter’s sales forecast for SMMT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Stock Forecast FAQ

What is SMMT’s average 12-month price target, according to analysts?

Based on analyst ratings, Summit Therapeutics’s 12-month average price target is 38.99.

What is SMMT’s upside potential, based on the analysts’ average price target?

Summit Therapeutics has 116.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SMMT a Buy, Sell or Hold?

Summit Therapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 2 hold ratings and 3 sell ratings.

What is Summit Therapeutics’s price target?

The average price target for Summit Therapeutics is 38.99. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $131.90 ,the lowest forecast is $13.00. The average price target represents 116.73% Increase from the current price of $17.99.

What do analysts say about Summit Therapeutics?

Summit Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of SMMT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Summit Therapeutics (SMMT) Stock Forecast & Price Target

SMMT Analyst Ratings

SMMT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Summit Therapeutics

SMMT Analyst Recommendation Trends

SMMT Financial Forecast

SMMT Earnings Forecast

SMMT Sales Forecast

SMMT Stock Forecast FAQ

Detailed List of Analyst Forecasts